65 results about "Ion channel blocker" patented technology

The invention pertains generally to the field of drug discovery science. More specifically, the invention refers to a drug screening assay and device that is used to test the effect of specific chemical compounds as use dependent ion channel blockers. The invention includes a unique method for stimulating cells with photoconductive stimulation and reading consequent cell ion channel activity with the optical imaging of fluorescent dyes.

The present invention describes a novel treatment for movement disorders, including tardive dyskinesia, tic disorders, Tourette's syndrome, and blepharospasm, and other focal dystonias. The treatment of the present invention utilizes agents that simultaneously act as NMDA-type glutamate receptor antagonists and GABA-A receptor agonists. Preferably these two activities are characteristic of a single agent, for example acamprosate. Alternatively, separate agents having these activities can be combined and administered together. The invention also provides a third agent that acts as a non-competitive NMDA-receptor blocking agent or ion channel blocker that augments the effect of the primary treatment. A particularly preferred ion channel blocking agent is magnesium. Alternatively, magnesium can be administered alone for prevention and treatment of movement disorders.

The invention provides compounds of Formula (I), or pharmaceutically acceptable salts thereof:The compounds, compositions, methods and kits of the invention are useful for the treatment of pain, itch, and neurogenic inflammation.

The present invention relates to a method of designing an ion channel blocker for an ion channel which includes providing an ion channel having an external vestibule portion and raising an antibody, binding portion, probe, or ligand specific to the external vestibule portion of the ion channel, where the antibody, binding portion, probe, or ligand inhibits ion transport through the ion channel. The present invention further relates to a method of inhibiting ion transport through an ion channel, a method for screening a drug for effectiveness as an ion channel blocker, and an antibody, binding portion, probe, or ligand.

The invention discloses a 1,2-diketone naphthalene compound which has a general structural formula (I) described in the specification, wherein Ar represents benzene ring, naphthalene ring, quinoline ring or isoquinoline ring, naphthalene diimide ring or coumarin ring; amino acid is directly connected with the Ar; when a substituent group exists on the Ar, R is an electron-withdrawing, electron-donating or neutral group. The invention further discloses a preparation method of the compound and application of the compound to preparation of inflammation-resistant and immunocompetence-resistant drugs. The compound is relatively good in inflammation and immunological competence resistance, is a CRAC (Ca<2+> release activated Ca<2+>) blocker with a novel structure, and can be used as a lead compound of the inflammation-resistant and immunocompetence-resistant drugs. According to the preparation method, the reaction condition is mild, raw materials are cheap and easily available, and the operation and the post-treatment process are simple.

The present invention relates to the use of blockers of ion channels regulated by the SUR subunit, for the treatment and / or prevention of eye diseases associated with ischemia and / or retinal excitotoxicity.

The invention provides compounds of Formula (I), or pharmaceutically acceptable salts thereof. The compounds, compositions, methods and kits of the invention are useful for the treatment of pain, cough, itch, and neurogenic inflammation.

The invention relates to a medicine composition for treating age-related hearing loss (ARHL). The medicine composition is characterized by comprising calcium ion channel blockers and / or free radical scavengers in effective treatment dosage. According to the medicine composition, two kinds of medicine with approvals of food and drug administration (FDA), i.e. the calcium ion channel blockers and free radical scavengers (antioxidant) relevant to free radical metabolic pathways are used, the two kinds of different chemical medicines are combined to be used in a synergistic action mode, the ARHL treatment effect can be improved, and in addition, the toxic and side effect of the medicine is reduced. The innovation points of the medicine composition are mainly in the following two aspects: (1) the medicine composition is focused on 11000 kinds of medicine with FDA approvals, and the medicine has high pharmacological activity and low side effects; and (2) medicine selected in the medicine composition respectively acts on different cell-molecle mechanism target sites, and the synergistic effect can be generated after the two kinds of medicine are combined to be used.